NCT07047755View on ClinicalTrials.gov

Trastuzumab Rezetecan Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

48

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

July 1, 2026

Study Completion Date

February 28, 2031

Conditions

Breast Cancer

Interventions

DRUG

Trastuzumab Rezetecan

Trastuzumab Rezetecan

DRUG

Pertuzumab

Pertuzumab

All Listed Sponsors

lead

Henan Cancer Hospital

OTHER_GOV